Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer.
Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential curability of at least some of these patients has encouraged the development of more complex, aggressive, and toxic multimodality treatment regimens.